Envista (NYSE:NVST) Price Target Raised to $27.00

Envista (NYSE:NVST) had its target price increased by Mizuho from $24.00 to $27.00 in a report issued on Tuesday morning,Benzinga reports. Mizuho currently has a neutral rating on the stock.

A number of other research analysts have also weighed in on the company. Wall Street Zen raised Envista from a “buy” rating to a “strong-buy” rating in a report on Monday, January 26th. Stifel Nicolaus set a $31.00 price objective on shares of Envista in a report on Friday, February 6th. Leerink Partners set a $35.00 target price on shares of Envista and gave the stock an “outperform” rating in a research note on Friday, February 6th. Robert W. Baird set a $30.00 target price on shares of Envista in a report on Friday, February 6th. Finally, Piper Sandler reissued a “neutral” rating and issued a $25.00 price target (up from $21.00) on shares of Envista in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.43.

Envista Stock Down 5.1%

Envista stock opened at $28.73 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.38 and a quick ratio of 2.04. The company’s 50-day moving average is $23.54 and its 200-day moving average is $21.48. The firm has a market capitalization of $4.72 billion, a PE ratio of 102.61, a P/E/G ratio of 2.07 and a beta of 1.01. Envista has a fifty-two week low of $14.22 and a fifty-two week high of $30.42.

Envista (NYSE:NVST) last posted its quarterly earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.Envista’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Sell-side analysts anticipate that Envista will post 1 earnings per share for the current year.

Insider Buying and Selling

In other Envista news, SVP Mischa Reis sold 9,675 shares of Envista stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the transaction, the senior vice president directly owned 32,382 shares of the company’s stock, valued at $971,460. The trade was a 23.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.66% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Ariel Investments LLC boosted its holdings in shares of Envista by 1.7% in the 2nd quarter. Ariel Investments LLC now owns 12,355,666 shares of the company’s stock valued at $241,430,000 after purchasing an additional 210,921 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Envista by 0.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 9,628,460 shares of the company’s stock worth $209,036,000 after buying an additional 90,586 shares during the last quarter. Franklin Resources Inc. boosted its stake in Envista by 16.7% in the second quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock valued at $175,011,000 after buying an additional 1,284,767 shares in the last quarter. Alliancebernstein L.P. grew its position in Envista by 34.0% in the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after acquiring an additional 1,547,656 shares during the last quarter. Finally, Clarkston Capital Partners LLC grew its position in Envista by 0.4% in the second quarter. Clarkston Capital Partners LLC now owns 4,703,330 shares of the company’s stock valued at $91,903,000 after acquiring an additional 16,583 shares during the last quarter.

Key Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q4 EPS and revenue beat drove early upside — Zacks reports NVST jumped after the quarter as EPS and revenue topped expectations and segments showed double-digit growth despite margin pressure. Read More.
• Positive Sentiment: Barclays raised its price target to $34 and moved the stock to “overweight,” giving Wall Street momentum and a stronger institutional narrative behind the rally. Read More.
• Positive Sentiment: Broker recognition: NVST was added to Zacks’ top growth list (Zacks Rank #1), which can attract momentum and growth-focused flows. Read More.
• Neutral Sentiment: Mizuho nudged its target higher to $27 but kept a neutral rating — a modest endorsement that is less bullish than some peers and may temper further upside. Read More.
• Negative Sentiment: Underlying profitability concerns: a Quiver summary shows Q4 revenue grew modestly, but Envista reported a large operating loss (~$337M) and net loss (~$372M), which weighs on the sustainability of the EPS beat and investor confidence. Cash remains healthy, but the losses are a material negative. Read More.
• Negative Sentiment: Insider and institutional selling: SVP Mischa Reis disclosed a sale (~9,675 shares) and major funds have trimmed stakes recently (e.g., Morgan Stanley, BlackRock, Point72), which can pressure the stock and prompt profit-taking. Read More. • Read More.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.